Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.60 |
| ▸ | FNTA | P49354 | 8/20 | 0.58 |
| ▸ | FNTB | P49356 | 8/20 | 0.58 |
| ▸ | PGGT1B | P53609 | 7/20 | 0.58 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9597693 | 0.94 | LTA4H (0.56) | LTA4HFNTAFNTBPGGT1BNAALAD2 | |
| SCHEMBL9597700 | 0.94 | LTA4H (0.56) | LTA4HFNTAFNTBPGGT1BNAALAD2 | |
| SCHEMBL8644611 | 0.93 | FNTA (0.62) | LTA4HFNTAFNTBPGGT1B | |
| SCHEMBL8644625 | 0.93 | FNTA (0.62) | LTA4HFNTAFNTBPGGT1B | |
| SCHEMBL6241495 | 0.91 | LTA4H (0.60) | LTA4HFNTAFNTBPGGT1BNAALAD2 | |
| SCHEMBL29630499 | 0.91 | NAALAD2 (0.57) | LTA4HFNTAFNTBPGGT1BNAALAD2 | |
| SCHEMBL30051274 | 0.91 | FNTA (0.62) | LTA4HFNTAFNTBPGGT1B | |
| SCHEMBL30209468 | 0.91 | FNTA (0.62) | LTA4HFNTAFNTBPGGT1B | |
| SCHEMBL29378966 | 0.90 | FNTA (0.58) | LTA4HFNTAFNTBPGGT1B | |
| SCHEMBL29892410 | 0.90 | NAALAD2 (0.67) | LTA4HNAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014097-A1 | CLADRIBINE REGIMEN FOR TREATING MULTIPLE SCLEROSIS | MERCK SERONO SA (CH) | 2026-01-15 | — | — | US | disclosed |
| EP-3693381-B1 | LIGAND BINDING MOLECULES AND USES THEREOF | VEGENICS PTY LTD (AU) | 2025-09-03 | — | — | EP | disclosed |
| US-12377056-B2 | Cladribine regimen for treating multiple sclerosis | MERCK SERONO SA (CH) | 2025-08-05 | — | — | US | disclosed |
| US-20250179131-A1 | IL-18 BINDING PROTEIN (IL-18BP) IN THE TREATMENT OF VEXAS | AB2 BIO SA (CH) | 2025-06-05 | — | — | US | disclosed |
| EP-4486367-A1 | IL-18 BINDING PROTEIN (IL-18BP) IN THE TREATMENT OF VEXAS | AB2 Bio SA (CH) | 2025-01-08 | — | — | EP | disclosed |
| US-20240301370-A1 | Ligand Binding Molecules and Uses Thereof | VEGENICS PTY LIMITED (AU) | 2024-09-12 | — | — | US | disclosed |
| US-20240190952-A1 | IL-18 Binding Protein (IL-18BP) and Antibodies for Treating Inflammatory Diseases | AB2 BIO SA (CH) | 2024-06-13 | — | — | US | disclosed |
| US-11926663-B2 | IL-18 binding protein (IL-18BP) and antibodies in inflammatory diseases | AB2 BIO SA (CH) | 2024-03-12 | — | — | US | disclosed |
| US-11866739-B2 | Ligand binding molecules and uses thereof | VEGENICS PTY LIMITED (AU) | 2024-01-09 | — | — | US | disclosed |
| US-11820817-B2 | IL-18 binding protein (IL-18BP) and antibodies in inflammatory diseases | AB2 BIO SA (CH) | 2023-11-21 | — | — | US | disclosed |
| CN-107660150-B | IL-18 binding proteins (IL-18 BP) and antibodies in inflammatory diseases | AB2生物股份有限公司 | 2023-10-24 | — | — | CN | disclosed |
| WO-2023166206-A1 | IL-18 BINDING PROTEIN (IL-18BP) IN THE TREATMENT OF VEXAS | AB2 BIO SA (CH) | 2023-09-07 | — | — | WO | disclosed |
| US-20230250164-A1 | IL-18 Binding Protein (IL-18BP) In Inflammatory Diseases | AB2 BIO SA (CH) | 2023-08-10 | — | — | US | disclosed |
| US-20230173021-A1 | IL-18 Binding Protein (IL-18BP) In Respiratory Diseases | AB2 BIO SA (CH) | 2023-06-08 | — | — | US | disclosed |
| EP-4185313-A1 | AVOIDING OR MINIMIZING SIDE-EFFECTS RELATED TO CAR-T-CELL THERAPY | AB2 Bio SA (CH) | 2023-05-31 | — | — | EP | disclosed |
| CN-116194131-A | Avoiding or minimizing side effects associated with CAR-T cell therapy | AB2生物股份有限公司 | 2023-05-30 | — | — | CN | disclosed |
| EP-4146174-A1 | IL-18 BINDING PROTEIN (IL-18BP) IN RESPIRATORY DISEASES | AB2 Bio SA (CH) | 2023-03-15 | — | — | EP | disclosed |
| US-20220401476-A1 | CAR-T-CELL THERAPY | AB2 BIO SA (CH) | 2022-12-22 | — | — | US | disclosed |
| US-11530263-B2 | IL-18 binding protein (IL-18BP) in inflammatory diseases | AB2 BIO SA (CH) | 2022-12-20 | — | — | US | disclosed |
| EP-3978526-A1 | IL-18 BINDING PROTEIN (IL-18BP) IN INFLAMMATORY DISEASES | AB2 Bio SA (CH) | 2022-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014097-A1 | CLADRIBINE REGIMEN FOR TREATING MULTIPLE SCLEROSIS | IL2, IFNAR1, IFNG | LTA4H 3260/4885FNTA 3793/4885FNTB 2226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.